Conn. Agencies Regs. § 21a-243-8

Current through May 9, 2024
Section 21a-243-8 - Controlled substances in schedule II

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in schedule II:

(a) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding Apomorphine, Dextrorphan, Nalbuphine, Naloxone, Nal-trexone, and their salts, but including the following: Raw opium, opium extracts, opium fluid extracts, powdered opium, granulated opium, tincture of opium, codeine, dihydroetorphine, ethylmorphine, etorphine hydrochloride, hydrocodone, hydromorhone, metopon, morphine, oripavine, oxycodone, oxymorphone and thebaine;
(2) Any salt, compound,isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium;
(3) Opium poppy and poppy straw;
(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine;
(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of opium poppy).
(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation, Dextrorphan and Levopropoxyphene excepted:
(1) Alfentanil;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) Bulk Dextropropoxyphene (nondosage forms);
(6) Carfentanil;
(7) Dihydrocodeine;
(8) Diphenoxylate;
(9) Fentanyl;
(10) Isomethadone;
(11) Levo-alphacetylmethadol or LAAM;
(12) Levomethorphan;
(13) Levorphanol;
(14) Metazocine;
(15) Methadone;
(16) Methadone-intermediate,4-cyano-2-dimethylamino-4,4-diphenylbutane;
(17) Moramide-Intermediate,2-methyl-3-morpholino-1,1-diphenyl-propane-carboxylic acid;
(18) Pethidine (Meperidine);
(19) Pethidine-Intermediate-A,4-cyano-1-methyl-4-phenylpiperidine;
(20) Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4-carboxylate;
(21) Pethidine-Intermediate-C, 1-methyl 4-phenylpiperidine-4-carboxylic acid;
(22) Phenazocine;
(23) Piminodine;
(24) Racemethorphan;
(25) Racemorphan;
(26) Remifentanil;
(27) Sufentanil;
(28) Tapentadol.
(c) Unless excepted or placed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:
(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
(2) Any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers;
(3) Methylphenidate;
(4) Phenmetrazine and its salts;
(5) Lisdexamfetamine and its salts, isomers and salts of isomers.
(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Amobarbital;
(2) Glutethimide;
(3) Pentobarbital;
(4) Phencyclidine; and
(5) Secobarbital.
(e) Hallucinogenic Substances:
(1) Nabilone.
(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances:
(1) Immediate precursor to Amphetamine and Methamphetamine; Phenylacetone (some trade names or other names); phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone;
(2) Immediate precursors to phencyclidine (PCP);
(A) 1-phencylohexylamine;
(B) 1-piperidinocyclohaxanecarbonitrile (PCC).
(g) Marijuana, (1) including any material, compound, mixture or preparation which contains its salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation, and (2) excepting any marijuana product that has been approved by the federal Food and Drug Administration or successor agency to have a medical use and reclassified in any schedule of controlled substances or unscheduled by the federal Drug Enforcement Administration or successor agency. Any marijuana product described in subdivision (2) of this subsection shall be included in the same schedule designated by the federal Drug Enforcement Administration or successor agency.
(h) Any schedule II controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.

Conn. Agencies Regs. § 21a-243-8

Effective July 23, 1987; Amended August 22, 1995; Amended March 6, 2000; Amended June 10, 2003; Amended June 10, 2011; Amended September 17, 2013; amended 4/30/2019; amended 2/10/2023